| [1] |
Srivastava S, Dadachova E. Recent advances in radionuclide therapy[J]. Semin Nucl Med, 2001, 31(4):330-341.
|
| [2] |
Krasner C, Joyce RM. Zevalin:90-Yttrium labeled anti-CD20(Ibritumomabtiuxetan), a new treatment for non-Hodgkin's lymphoma[J]. Curr Pharm Biotechol, 2001, 2(4):341-349.
|
| [3] |
Wagner HN Jr, Wiseman GA, Marcus CS, et al. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y labelled anti-CD20 monoclonal antibody[J]. J Nucl Med, 2002, 43(2):267-272.
|
| [4] |
Hainsworth JD. Monoclonal antibody therapy in lymphoid malignancies[J]. Oncologist, 2000, 5(5):376-384.
|
| [5] |
Wiseman GA, White CA, Sparks RB, et al. Biodistribution and dosimetry results froma phase Ⅲ prospectively randomized controlled trial ZevalinTM radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma[J]. Critical Revi Oncol Hematol,2001, 39(2):181-194.
|
| [6] |
Janakiraman N, Gutheil J, Schilder RJ, et al. Phase Ⅰ/Ⅱ trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refratory CD20(+) B-cell non-Hodgkin's lymphoma[J]. J Clin Oncol, 1999, 17(12):3793-3803.
|